Business Wire (September 17, 2008)
Permanent Link:
http://vlex.com/vid/biovail-acquires-prestwick-pharmaceuticals-56077015
Id. vLex: VLEX-56077015
Acceda a este documento
y pruebe vLex GRATIS durante 3 días
Business
Business, general
Pharmaceutical industry
Company acquisition/merger
Huntington's disease
Mergers, acquisitions and divestments
Biovail Acquires Prestwick Pharmaceuticals.
Represents Ongoing Implementation of Company's New Strategic Focus
Provides Company's First Commercial Product in Specialty CNS Markets TORONTO -- Biovail Corporation (NYSE:BVF) (TSX:BVF) today announced it has acquired Prestwick Pharmaceuticals, Inc., a privately held, U.S.-based pharmaceutical company that holds the Canadian and U.S. licensing rights to Xenazine[R] (tetrabenazine tablets). Xenazine[R] was recently approved by the United States Food and Drug Administration (FDA) for the treatmen...Try vLex for FREE for 3 days
Access legal information from United States including:
Try vLex without any commitment for 3 days and see why you need it.
3
days of Free Access
If you are already a vLex customer, Access Here